Dan Cappabianca
Novel CAR T Cell therapy development in translational and bench top settings
Tag: gene editing
The advent of the CRISPR-CAS9 technique gives researchers the ability to make precise changes to the DNA of, theoretically, any living organism that has DNA. That precision is particularly meaningful for treatment of diseases caused by well-known faults in genes — otherwise incurable diseases such as sickle cell anemia, the fatal lung disorder cystic fibrosis, and the blindness-causing Leber congenital amaurosis. CRISPR-Cas9 could be a way to prevent or reverse those disorders.
UW Researchers Devise Approach to Treat Rare, Incurable Form of Blindness
WID’s Kris Saha was among UW–Madison researchers who have published a proof-of-concept method to correct an inherited form of macular degeneration that causes blindness, and that is currently untreatable.
WPR: An Exciting Development, CRISPR Lets UW-Madison Researchers Edit Genes
WID’s Kris Saha spoke to Wisconsin Public Radio to answer questions about gene editing technology CRISPR in response to a question received by WHYsconsin.
Benjamin Grindel
Set up and analyze qPCR samples for use in CAR T-cell identification in in vivo and in vitro samples.
Human Nature Screening
The the MS Biotechnology program at UW and the Wisconsin Institute for Discovery are partnering to screen the documentary film “Human Nature”, an exploration of gene editing and its implications both biological and ethical.
Xiaoya Zhang
Epigenetic control of cell identity in development and somatic cell reprogramming.
Should We Alter the Human Genome? Let Democracy Decide
WID’s Krishanu Saha and colleagues J. Benjamin Hurlbut and Sheila Jasanoff write in Scientific American about germ line editing and the need for more scientific and moral clarity.
Tiny Capsules Packed with Gene-Editing Tools Offer Alternative to Viral Delivery of Gene Therapy
An interdisciplinary pair of WID researchers has developed a new nanocapsule delivery method for delivering the CRISPR-Cas9 gene editing tool. The new system could be used for many types of gene therapies.
Josh Rawlins
Human cell engineering including CRISPR gene editing and epigenetic reprogramming
Shivani Saxena
Engineering cells and organism via genome editing and studying the delivery method for CRISPR/Cas9
Amulya Suresh
CRISPR-Cas9 Strategy to Generate DOT1L-Deficient Embryonic Stem Cells to Study Pluripotency
Randolph Ashton Named SCRMC Associate Director
WID’s Randolph Ashton, assistant professor of biomedical engineering, is the new associate director for UW–Madison’s Stem Cell and Regenerative Medicine Center.
Wisconsin State Journal: At UW-Madison, 500 Scientists Studying Stem Cells 20 Years After Discovery
The Wisconsin State Journal, as part of its feature highlighting stem cell research at UW 20 years after James Thomson’s discovery, highlights WID researchers Randolph Ashton and Kris Saha.
UW–Madison Researchers Developing Methods to Edit Genes in Brain Cells
A second WID-led team joins NIH’s Somatic Cell Genome Editing Consortium with a grant to study new methods of delivering the CRISPR/Cas9 system to the brain.
Scientists Seek to Improve Quality Control for Genome Editing Therapies in the Eye
UW researchers led by WID’s Kris Saha join the National Institutes of Health’s Somatic Cell Genome Editing Consortium with a major collaborative award.
Micah Dombroe
Lab Manager
Genomic DNA sequencing and viral production. Facilitate various administrative functions.